title: Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients.
abstract: BACKGROUND
  Skin toxicity has recently been recognized as a dose-limiting toxicity of antineoplastic therapy.
  
  
  CONCLUSIONS
  We report severe skin toxicity observed in anthracycline-pretreated metastatic breast cancer patients receiving the combination of capecitabine and weekly paclitaxel.
authors.affiliation: Department for Medical Oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000, Belgrade, Serbia. susnjars@ncrc.ac.yu
authors.forename: Snezana
authors.initials: S
authors.lastname: Susnjar
authors.forename: Snezana M
authors.initials: SM
authors.lastname: Bosnjak
authors.forename: Sinisa
authors.initials: S
authors.lastname: Radulovic
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D006801:Humans; D009362:Neoplasm Metastasis / Q000188:drug therapy; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D012871:Skin Diseases / Q000139:chemically induced*
chemical_list: D003841:Deoxycytidine; D000069287:Capecitabine; D017239:Paclitaxel; D005472:Fluorouracil
references.citation: Oncology. 2004;67(2):117-22
references.pmid: 15539915
references.citation: J BUON. 2007 Apr-Jun;12(2):189-96
references.pmid: 17600871
references.citation: J Clin Oncol. 2004 Jun 15;22(12):2321-7
references.pmid: 15197193
references.citation: Cancer. 2000 May 15;88(10):2367-71
references.pmid: 10820360
references.citation: J Clin Oncol. 2001 Nov 15;19(22):4216-23
references.pmid: 11709565
references.citation: Oncology. 2006;71(1-2):54-60
references.pmid: 17344671
references.citation: Ann Oncol. 1998 Oct;9(10):1139-40
references.pmid: 9834830
references.citation: Eur J Cancer. 2004 Feb;40(3):352-7
references.pmid: 14746852
references.citation: J Clin Oncol. 1999 Jun;17(6):1915-25
references.pmid: 10561233
references.citation: Ann Oncol. 2001 May;12(5):605-14
references.pmid: 11432617
references.citation: Cancer. 2001 Oct 1;92(7):1759-68
references.pmid: 11745247
references.citation: Clin Cancer Res. 1998 Apr;4(4):1013-9
references.pmid: 9563897
references.citation: Ann Oncol. 2003 Oct;14(10):1588-9
references.pmid: 14504063
references.citation: J Clin Oncol. 2002 Nov 1;20(21):4404-5; author reply 4405
references.pmid: 12409345
references.citation: Br J Cancer. 2004 May 4;90(9):1740-6
references.pmid: 15150624
references.citation: Lancet. 2001 Mar 24;357(9260):910
references.pmid: 11289346
references.citation: J Clin Oncol. 2006 Sep 20;24(27):4384-90
references.pmid: 16926223
references.citation: Ann Oncol. 2003 Feb;14(2):333-7
references.pmid: 12562663
references.citation: Ann Oncol. 2006 Jan;17(1):79-84
references.pmid: 16284056
references.citation: J Clin Oncol. 1998 Oct;16(10):3353-61
references.pmid: 9779712
references.citation: Eur J Oncol Nurs. 2004;8 Suppl 1:S31-40
references.pmid: 15341880